Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
暂无分享,去创建一个
John Kuriyan | Yibing Shan | D. Shaw | Y. Shan | J. Kuriyan | N. Jura | David E Shaw | Natalia Jura | Xiaoxian Cao | Xiaoxian Cao | Yibing Shan
[1] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[2] John Kuriyan,et al. Crystal structure of the Src family tyrosine kinase Hck , 1997, Nature.
[3] Krystal J Alligood,et al. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.
[4] R. Landgraf,et al. Heregulin reverses the oligomerization of HER3. , 2000, Biochemistry.
[5] L. Cantley,et al. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor , 1994, Molecular and cellular biology.
[6] R. Stein,et al. Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis , 2006, BMC Evolutionary Biology.
[7] A. Ullrich,et al. Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. , 1995, The EMBO journal.
[8] M. Lemmon,et al. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface , 2004, FEBS letters.
[9] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[10] John Kuriyan,et al. Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.
[11] F. Sicheri. Faculty Opinions recommendation of Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. , 2007 .
[12] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[13] I. Ellis,et al. c-erbB-4 protein expression in human breast cancer , 2000, British Journal of Cancer.
[14] Stefan Knapp,et al. Structure of the Pseudokinase VRK3 Reveals a Degraded Catalytic Site, a Highly Conserved Kinase Fold, and a Putative Regulatory Binding Site , 2009, Structure.
[15] John Kuriyan,et al. Structural Basis for the Inhibition of Tyrosine Kinase Activity of ZAP-70 , 2007, Cell.
[16] R. Dror,et al. A conserved protonation-dependent switch controls drug binding in the Abl kinase , 2009, Proceedings of the National Academy of Sciences.
[17] N. Bundred,et al. Absence of HER4 Expression Predicts Recurrence of Ductal Carcinoma In situ of the Breast , 2005, Clinical Cancer Research.
[18] Sung-Hou Kim,et al. Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.
[19] J. Zou,et al. Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.
[20] K. Shokat,et al. Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.
[21] John Kuriyan,et al. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.
[22] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[23] Kornelia Polyak,et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.
[24] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[25] François Stricher,et al. The FoldX web server: an online force field , 2005, Nucleic Acids Res..
[26] M. Moasser,et al. The epidermal growth factor receptor family: Biology driving targeted therapeutics , 2008, Cellular and Molecular Life Sciences.
[27] H. Kim,et al. Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. , 1997, The Biochemical journal.
[28] Ron Bose,et al. Mechanism of activation and inhibition of the HER4/ErbB4 kinase. , 2008, Structure.
[29] A. Pozzi,et al. The juxtamembrane region of the EGF receptor functions as an activation domain. , 2009, Molecular cell.
[30] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[31] T. Südhof,et al. CASK Functions as a Mg2+-Independent Neurexin Kinase , 2008, Cell.
[32] Randy J. Read,et al. Electronic Reprint Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination , 2022 .
[33] S. Harrison,et al. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. , 1999, Molecular cell.
[34] Kian Kani,et al. The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation. , 2005, Biochemistry.
[35] John Kuriyan,et al. A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain , 2006, PLoS biology.
[36] Hyun-soo Cho,et al. Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether , 2002, Science.
[37] W. Gullick,et al. Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera. , 1994, The EMBO journal.
[38] L. Cantley,et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[39] J. Baselga,et al. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.
[40] J. Kuriyan,et al. The Conformational Plasticity of Protein Kinases , 2002, Cell.